Pharmacological inhibition of the CK1 family members has been investigated as potential therapy in preclinical studies involving neurodegenerative diseases [41], obesity [42], behavioral disorders [43], alcohol [44] or opioid addiction [45] and several cancer types [12]. Here, CSNK1A1 is linked to cancer.